Back to Journals » Journal of Pain Research » Volume 12

Population Pharmacokinetic Modeling Of Flurbiprofen, The Active Metabolite Of Flurbiprofen Axetil, In Chinese Patients With Postoperative Pain [Expression Of Concern]

Authors Zhang J, Zhang H , Zhao L, Gu J , Feng Y, An H

Received 18 September 2019

Accepted for publication 18 September 2019

Published 27 September 2019 Volume 2019:12 Pages 2799—2800


Zhang J, Zhang H, Zhao L, Gu J, Feng Y, An H. Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain. J Pain Res. 2018;11:3061– 3070.

The Editor-in-Chief and Publisher of the Journal of Pain Research wish to issue an Expression of concern for the published article.

A reader raised concerns to the Editor about the validity of the data presented in the published article. It was alleged three authors of the present article, Zhang H, Feng Yand Gu J, had previously published the results of the study in the article: 

Zhang H, Feng Y, Gu J. Distribution of flurbiprofen axetil in cerebral-spinal fluid after intravenous administration. Chin J Anaesthesiol. 2011;31(04):432– 434. doi:10.3760/cma.j.issn.0254-1416.2011.04.012.

It was also alleged the clinical trial registration (CTR) number (ChiCTR-TRC-11001791) provided in the published article was taken from an unrelated study and had no association with the current study.

Read the original article

Corrigendum for the original article paper has been published



Creative Commons License © 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.